HHS told FDA not to enforce its peptide rules for six compounds: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Pharmacies can compound them under ten conditions. This is not approval, and FDA's own scientists opposed it.
On Wednesday, October 28, the Department of Health and Human Services filed a notice that changes what a licensed U.S. pharmacy can put in a syringe. Published in the Federal Register today, October 30, it is called the "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Its Appendix A names six peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500.
None of them is FDA-approved. None has been added to the federal list of ingredients pharmacies are allowed to use. What changed is narrower and stranger than approval. The Secretary of HHS has announced that the government does not intend to pursue pharmacies, physicians, or federal facilities that compound those six under a set of stated conditions — while FDA writes the rules that would decide the question the ordinary way.
For two years, people who want these compounds legally have been waiting for a door to open. It opened this week. But HHS, not the FDA, is holding it, and FDA's own scientists spent the summer arguing it should stay shut.
The backstory is the part most coverage will skip, and it explains everything about how much weight this policy carries.
On July 23 and 24, FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list — the register of ingredients compounding pharmacies may legally use. FDA's career scientists had formally recommended against listing every single one. The committee voted to back six anyway: BPC-157, KPV, and TB-500 each passed 8 to 6 with one abstention; MOTS-c passed 7 to 5; epitalon passed 7 to 4; semax passed 8 to 5. The seventh, emideltide (the sleep peptide DSIP), was rejected 6 to 7.
Before the meeting, FDA added eight temporary voting members to the panel. The Associated Press reported that more than a half-dozen of the newcomers had connections to the peptide industry, and panel members with academic backgrounds mostly voted no. One of them, Dr. Elizabeth Rebello of MD Anderson, said she was "concerned we're responding to a market-induced demand rather than a decision based in solid science."
Formally adding these peptides to the bulks list would require notice-and-comment rulemaking, a process that takes many months and ends with a rule FDA's scientists say the evidence does not support. According to the AP, HHS originally wanted FDA to draft that rule, was told its staff would not support declaring the peptides safe, and changed approach. The document was written primarily at HHS, signed by Secretary Robert F. Kennedy Jr., and carries the docket of the Office of the Assistant Secretary for Health — not FDA. Six people familiar with its development told the AP that most FDA drug staffers opposed it and had limited input.
That is the unusual part. Compounding decisions have almost always come from FDA, through FDA. Federal law, however, gives HHS authority over drug regulation, delegated down to the FDA. This week, HHS used that authority directly, and it chose a mechanism that never requires anyone to declare the peptides safe: enforcement discretion, which is a policy about enforcement rather than a change in the law.
The core text is short. Because these substances are not yet on the 503A bulks list, compounding them would normally expose a pharmacy to federal action. The notice states that HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" that compounds a drug using one of the six peptides in Appendix A. It does not establish rights for anyone, and HHS explicitly says it may revisit the policy in whole or in part if a safety signal or product quality issue turns up.
Who is covered matters: state-licensed 503A pharmacies, federal facilities, and licensed physicians. The larger 503B outsourcing facilities are not covered. If a high-volume manufacturer makes your vial, this policy gives you nothing.
Each peptide also comes with a fixed chemical identity and a fixed route. You cannot compound a version of it that departs from Appendix B:
And enforcement discretion applies only if every condition is met: the bulk substance comes from an FDA-registered original manufacturer in CGMP compliance, with a valid certificate of analysis covering identity, purity, and potency, including tests for endotoxins, heavy metals, and microbes; the product is made against a valid patient-specific prescription; the finished drug contains a single active ingredient — which rules out stacks and blends outright; serious adverse events and quality problems are reported to FDA's MedWatch system and to the relevant state authorities; labeling reads "This is a compounded drug product. Not for resale."; and any co-packaged delivery device is an FDA 510(k)-cleared syringe. For oral forms, the compounder must keep documentation of adequate bioavailability.
HHS's stated rationale is market-shaped rather than clinical: the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients," and "advances patient choice and freedom while appropriately protecting patient safety." An HHS spokesperson told CNN the policy "does not grant FDA approval or establish clinical safety and effectiveness" and requires "patient-specific prescriptions, traceable ingredients, quality testing and safety reporting."
Read the other half of the ledger, because it is longer than the first half.
These six peptides are still not approved drugs. They have not entered the 503A bulks list or Category 1; that still requires a final rule after public comment. The claims people buy them for — BPC-157 for ulcerative colitis and gut repair, TB-500 and KPV for wound healing, MOTS-c for obesity and osteoporosis, semax for migraine, epitalon for insomnia — remain unproven in approved trials. In FDA's June briefing documents, agency scientists could find no published human studies at all for TB-500, KPV, and MOTS-c, and rated the rest insufficient for their proposed uses. Emideltide, the one the committee rejected, is not covered.
Buying vials labeled "research use only" online is also unchanged: those remain unapproved new drugs when sold for human use, and the policy does not touch that market.
State law is a separate question. State pharmacy boards are not bound by a federal non-enforcement notice, so the same peptide can be permitted in one state and contested in the next. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, welcomed the decision as a "more accountable alternative" to illicit supply — "far too many patients are obtaining peptides from illicit suppliers with little assurance about what's actually in the vial" — while flagging the open questions: when the policy actually takes effect, how testing will be validated, and how states will respond.
The conditions are aimed at a real problem. In our June analysis of independent testing data, the Finnrick Analytics platform had logged 7,829 peptide samples from 224 vendors, with roughly one-third of products failing basic quality checks. Sourcing from registered facilities, certificates of analysis, and mandatory adverse-event reporting is the regulatory answer to that spread. Whether it works in practice is a different question.
The opposition is organized and on the record. Dr. Robert Steinbrook of Public Citizen's Health Research Group called the move reckless and unilateral: "By allowing unproven and potentially unsafe peptides to be manufactured, marketed and prescribed without concern about potential federal enforcement actions, Kennedy has undermined the FDA and threatened public health." The Partnership for Safe Medicines filed a citizen petition last week urging FDA to ignore its own committee's recommendation. Researchers at the Center for Science in the Public Interest wrote in a JAMA Viewpoint that the size of an unregulated market should not decide the question, and that letting compounders sell these substances without evidence removes the incentive for anyone to run the clinical trials that could earn approval.
The money is on the other side. Hims & Hers and Noom have both announced plans to offer peptides if federal policy eased; Wall Street analysts put the reachable market at two to three billion dollars a year. Kennedy has described himself as a "big fan" of peptides and has said he used BPC-157 for a muscle injury. Peter Lurie of CSPI questioned the timing as well, noting the policy lands days before the midterm election.
Both things can be true in the same week: the quality floor for these six just rose, and the evidence behind them did not move at all.
Four things, in roughly this order.
First, the comment window. Written comments are due two weeks after today's publication, on the docket HHS-OASH-2026-0496.
Second, the effective date and the state response. The Alliance for Pharmacy Compounding is still asking when the policy takes effect and how state boards will treat it. A patchwork of state rules would give patients the access question on paper and the restriction in practice.
Third, formal rulemaking. Adding these peptides to the 503A bulks list the ordinary way — through FDA notice-and-comment — remains the only change that confers actual legal status. Enforcement discretion lasts only until a final rule addresses each substance, and can be revisited sooner if a safety signal appears.
Fourth, the next committee round. Before February 2027, the compounding panel is scheduled to consider GHK-Cu, LL-37, dihexa, melanotan II, and PEG-MGF. The July vote covered seven peptides; the queue is longer.
We exist to give this question a straight answer instead of a sales pitch. The straight answer today: if you are in the U.S. and have wanted a real prescription route for one of these six peptides, this week was genuinely good news — a licensed pharmacy, a single tested ingredient, a doctor's signature, and a reporting trail. If you are evaluating whether any of them works, nothing changed. A committee vote and a non-enforcement notice are political and legal events, not clinical ones, and three of the six still have no published human studies behind their most popular uses.
The honest posture is both at once: access widened, evidence did not — and "legal to compound" is a manufacturing status, never a claim about what a compound will do for you.
Evidence grade: B — Current-status and policy claims rest on primary documents: the Federal Register notice (FR Doc. 2026-22192, docket HHS-OASH-2026-0496, filed October 28, published October 30, 2026) and the HHS policy text with Appendices A and B. Vote tallies, quotes, and process reporting come from the Associated Press, NPR, CNN, STAT, RAPS, Fierce Pharma, and Public Citizen statements. The grade is not higher because no new clinical evidence was published this week, and the policy's real-world enforcement remains untested.
Sources: Federal Register, FR Doc. 2026-22192 (filed 28 Oct, published 30 Oct 2026), docket HHS-OASH-2026-0496 · HHS draft policy with Appendices A and B, hhs.gov · Associated Press, 23 Jul and 28 Oct 2026 · NPR and CNN, 28–29 Oct 2026 · RAPS, Fierce Pharma, AJMC, Oct 2026 · Public Citizen statement, 28 Oct 2026 · McDermott PCAC vote summary, Jul 2026.
Oria BioStack publishes evidence-graded explainers on peptides and metabolic medicine. This article is educational and is not medical or legal advice. Every compound named here has a different regulatory status, and none of the six is FDA-approved for human use. Talk to a licensed clinician before making any decision about compounded peptides.
